Collaborative Working Project between Greater Glasgow & Clyde Health Board and Pfizer Limited
Developing and coordinating clinical pathways to review and optimise the diagnosis and treatment of patients with a suspected or confirmed diagnosis of cardiac amyloidosis across Greater Glasgow & Clyde.
Background
Cardiac Amyloidosis (CA) is a progressive infiltrative heart muscle disease, caused by the accumulation of insoluble amyloid fibrils in the heart muscle (myocardium). The resulting cardiomyopathy eventually progresses to end-stage heart failure. Life expectancy without access to specialised treatment is poor.
Project
This project is aimed at supporting, via a collaborative working agreement between the NHS Greater Glasgow & Clyde Health Board and Pfizer UK Ltd., the delivery of a comprehensive plan to educate, improve disease awareness, develop operational capabilities and understand and deliver patient focused services with equity, all targeted at improving clinical pathways across Greater Glasgow & Clyde. The project will fund the provision of a band 7 Advanced Nurse Practitioner (ANP) for amyloidosis and a band 4 Multi-Disciplinary Team (MDT) Co Ordinator post to support the administration of the amyloidosis service. This approach aims to ensure that there is a thorough and coordinated clinical pathway to assess amyloidosis patients through local multi-disciplinary teams and ensure access to diagnostics and approved treatments in a timely manner.
Benefits
Benefits to patients
Improved access to specialised diagnostics, clinics and treatments.
Coordinated patient pathway for cardiac amyloidosis.
Improve adherence to medicines through ANP specialist support.
Supporting improved outcomes for amyloid patients (e.g., improve decision making by specialist multi-disciplinary team (MDT), access to expert diagnostics and experience in treatment decision making).
Reduced variation between hospitals across the network for all CA patients entering the clinical pathway.
Benefits to the NHS
Increased cross hospital collaboration.
Improved clinical pathways.
Reduced cardiology waiting times.
Improved access to diagnostics.
Improved education on cardiac amyloidosis.
Benefits to Pfizer
The project may result in the identification of patients who are eligible for appropriate treatments prescribed in line with current national and local guidelines (which may include licensed Pfizer medicine).
Accelerated initiation of appropriate licensed treatments for patients diagnosed with cardiac amyloidosis under the guidance of an expert clinician.
Increased understanding of service provision and patient pathway design.
Outcomes
To improve the care of patients with cardiac amyloidosis by improving awareness, education, equity of access and clinical pathways across the Greater Glasgow & Clyde area.
Proposed term of the collaborative working project
Start date: 1st June 2025
End date: 31st May 2026
Resource allocation
Greater Glasgow & Clyde Health Board will contribute:
• Additional diagnostic testing funding: £24,624.00
• Human resource support: 640 hours £22,400.00
Pfizer UK Ltd will contribute:
• Advanced Nurse Practitioner & MDT CO Ordinator funding: £109,692.00
• Human resource support: 150 hours £5,250.00
Pfizer is committed to being transparent about the relationships we have with other organisations.
Find out about the donations and grants we make available to support healthcare, scientific research and education.